Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Following Latest Nu.Q Data Jul 13, 2022 09:11AM
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company" May 18, 2022 06:17AM
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Apr 26, 2022 08:51AM
Pre-Open Stock Movers 03/10: (MNOV) (KOSS) (CDXC) Higher; (TUP) (AVID) (JNCE) Lower (more...) Mar 10, 2021 09:29AM
After-Hours Stock Movers 03/09: (MNOV) (OM) (NARI) Higher; (AVID) (CLNE) (XM) Lower (more...) Mar 9, 2021 05:46PM


Mar 9, 2021 04:08PM Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight
Feb 12, 2021 09:25AM VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
Feb 10, 2021 09:23AM Volitionrx Limited (VNRX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
Feb 10, 2021 09:18AM VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
Feb 9, 2021 04:02PM Volitionrx Limited (VNRX) to Offer Common Stock
Feb 9, 2021 04:01PM VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
Sep 6, 2017 04:30PM VolitionRx Limited to Attend Multiple Conferences in September